MERKEL CELL CARCINOMA

This early-phase study tested a new treatment called BT-001, which is injected directly into tumors. It was given alone and combined with an existing immunotherapy drug (pembrolizumab) to people with advanced cancers that had spread. The main goals were to find a safe dose and se…

This study tested whether combining two immunotherapy drugs could help control several types of advanced cancer. It involved 77 people with cancers like skin cancer, lung cancer, and breast cancer. The trial was terminated early because the drug supply was discontinued, so resear…

This early-stage study tested a new radioactive drug (225Ac-SSO110) given alongside standard immunotherapy for people with advanced small cell lung cancer or Merkel cell carcinoma. The main goal was to find a safe dose and see if the drug combination showed any early signs of fig…

This early-stage study tested a new drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety, how the body processes it, and what side effects it might cause. The trial was termina…

This early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the b…

This study tested whether adding an experimental drug called NT-I7 to an existing immunotherapy (atezolizumab) could help control advanced skin cancers. It focused on patients whose cancers had not responded to or had returned after similar treatments. The main goals were to find…